Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 6/20 | 0.46 |
| ▸ | BCHE | P06276 | 5/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | CACNB4 | O00305 | 1/20 | 0.46 |
| ▸ | CACNA1A | O00555 | 1/20 | 0.46 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.46 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.46 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.46 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.46 |
| ▸ | CACNG3 | O60359 | 1/20 | 0.46 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.46 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11832846 | 0.91 | BCHE (0.51) | MAPTMAOAMAOBACHEBCHE | |
| Hydrochloric Acid SCHEMBL11833417 | 0.90 | MAPT (0.53) | MAPTMAOAMAOBACHEBCHE | |
| Hydrochloric Acid SCHEMBL11833405 | 0.88 | MAPT (0.53) | MAPTMAOAMAOBACHEBCHE | |
| SCHEMBL6610838 | 0.84 | ACHE (0.62) | MAPTMAOAACHEBCHEALDH1A1 | |
| Hydrochloric Acid SCHEMBL6606586 | 0.83 | ACHE (0.63) | MAPTMAOAACHEBCHEALDH1A1 | |
| SCHEMBL7976500 | 0.81 | ALDH1A1 (0.54) | MAPTACHEBCHEALDH1A1TSHR | |
| Hydrochloric Acid SCHEMBL7976524 | 0.80 | ALDH1A1 (0.56) | MAPTACHEBCHEALDH1A1TSHR | |
| SCHEMBL6608441 | 0.80 | MAPT (0.70) | MAPTACHEBCHEALDH1A1TSHR | |
| SCHEMBL17792389 | 0.80 | MAPT (0.52) | MAPTACHEBCHEAPPGRIN1 | |
| SCHEMBL16210526 | 0.80 | PDE5A (0.53) | MAPTACHEBCHECYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11851427-B2 | Phosphodiesterase inhibitors and uses thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-12-26 | — | — | US | disclosed |
| US-20210130349-A1 | NOVEL PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2021-05-06 | — | — | US | disclosed |
| US-20210130349-A1 | NOVEL PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2021-05-06 | — | — | US | disclosed |
| US-10899756-B2 | Phosphodiesterase inhibitors and uses thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2021-01-26 | — | — | US | disclosed |
| EP-3022205-B1 | NOVEL PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | UNIV COLUMBIA (US) | 2020-02-05 | — | — | EP | disclosed |
| EP-3022205-B1 | NOVEL PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | UNIV COLUMBIA (US) | 2020-02-05 | — | — | EP | disclosed |
| US-20160152612-A1 | NOVEL PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-06-02 | — | — | US | disclosed |
| US-20160152612-A1 | NOVEL PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-06-02 | — | — | US | disclosed |
| US-20160152612-A1 | NOVEL PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-06-02 | — | — | US | disclosed |
| EP-3022205-A2 | NOVEL PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | The Trustees of Columbia University in the City of New York (US) | 2016-05-25 | — | — | EP | disclosed |
| WO-2015009930-A2 | NOVEL PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2015-01-22 | — | — | WO | disclosed |
| WO-2015009930-A2 | NOVEL PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2015-01-22 | — | — | WO | disclosed |
| US-20130012505-A1 | BENZONAPHTHYRIDINAMINES AS AUTOTAXIN INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-01-10 | — | — | US | disclosed |
| US-20130012505-A1 | BENZONAPHTHYRIDINAMINES AS AUTOTAXIN INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-01-10 | — | — | US | disclosed |
| WO-2011116867-A1 | BENZONAPHTHYRIDINAMINES AS AUTOTAXIN INHIBITORS | MERCK PATENT GMBH (DE) | 2011-09-29 | — | — | WO | disclosed |
| EP-0997462-B1 | NOVEL NAPHTHYRIDINE DERIVATIVES OR SALTS THEREOF | NIPPON KAYAKU KK (JP) | 2004-12-22 | — | — | EP | disclosed |
| US-6433174-B1 | Process for producing novel naphthyridine derivatives | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2002-08-13 | — | — | US | disclosed |
| EP-1142892-A1 | PROCESSES FOR THE PREPARATION OF NOVEL NAPHTHYRIDINE DERIVATIVES | Nippon Kayaku Kabushiki Kaisha (JP) | 2001-10-10 | — | — | EP | disclosed |
| US-6294547-B1 | Naphthyridine deratives or salts thereof | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2001-09-25 | — | — | US | disclosed |
| EP-0997462-A1 | NOVEL NAPHTHYRIDINE DERIVATIVES OR SALTS THEREOF | Nippon Kayaku Kabushiki Kaisha (JP) | 2000-05-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160152612-A1 | NOVEL PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | PDE5A, PDE2A, PDE3A | MAPT 1752/4885MAOA 112/4885MAOB 256/4885 |
| US-11851427-B2 | Phosphodiesterase inhibitors and uses thereof | PDE5A, PDE2A, PDE3A | MAPT 1911/4885MAOA 120/4885MAOB 253/4885 |
| US-10899756-B2 | Phosphodiesterase inhibitors and uses thereof | PDE5A, PDE2A, PDE3A | MAPT 1911/4885MAOA 120/4885MAOB 253/4885 |
| US-20210130349-A1 | NOVEL PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | PDE5A, PDE2A, PDE3A | MAPT 1752/4885MAOA 112/4885MAOB 256/4885 |
| US-20130012505-A1 | BENZONAPHTHYRIDINAMINES AS AUTOTAXIN INHIBITORS | ENPP2, LYPLAL1, LYPLA1 | MAPT 3567/4885MAOA 72/4885MAOB 126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.